WO2000042973A3 - Homing pro-apoptotic conjugates and methods of using same - Google Patents

Homing pro-apoptotic conjugates and methods of using same Download PDF

Info

Publication number
WO2000042973A3
WO2000042973A3 PCT/US2000/001602 US0001602W WO0042973A3 WO 2000042973 A3 WO2000042973 A3 WO 2000042973A3 US 0001602 W US0001602 W US 0001602W WO 0042973 A3 WO0042973 A3 WO 0042973A3
Authority
WO
WIPO (PCT)
Prior art keywords
homing
mammalian cell
methods
same
apoptotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/001602
Other languages
French (fr)
Other versions
WO2000042973A2 (en
Inventor
H Michael Ellerby
Dale E Bredesen
Renata Pasqualini
Erkki I Ruoslahti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Priority to AU33486/00A priority Critical patent/AU770381B2/en
Priority to EP00911617A priority patent/EP1150701A4/en
Priority to JP2000594432A priority patent/JP4531267B2/en
Priority to CA002359633A priority patent/CA2359633A1/en
Publication of WO2000042973A2 publication Critical patent/WO2000042973A2/en
Publication of WO2000042973A3 publication Critical patent/WO2000042973A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a homing pro-apoptotic conjugate, which includes a tumor homing molecule that selectively homes to a selected mammalian cell type or tissue linked to an antimicrobial peptide, where the conjugate is selectively internalized by the mammalian cell type or tissue and exhibits high toxicity thereto, and where the antimicrobial peptide has low mammalian cell toxicity when not linked to the tumor homing molecule. A homing pro-apoptotic conjugate of the invention can be, for example, CNGRC-GG-D(KLAKLAK)2 or ACDCRGDCFC-GG-D(KLAKLAK)2. The conjugates of the invention are useful, for example, for treating a patient with a tumor having angiogenic vasculature.
PCT/US2000/001602 1999-01-22 2000-01-21 Homing pro-apoptotic conjugates and methods of using same Ceased WO2000042973A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU33486/00A AU770381B2 (en) 1999-01-22 2000-01-21 Homing pro-apoptotic conjugates and methods of using same
EP00911617A EP1150701A4 (en) 1999-01-22 2000-01-21 Homing pro-apoptotic conjugates and methods of using same
JP2000594432A JP4531267B2 (en) 1999-01-22 2000-01-21 Homing pro-apoptotic conjugates and methods of using homing pro-apoptotic conjugates
CA002359633A CA2359633A1 (en) 1999-01-22 2000-01-21 Homing pro-apoptotic conjugates and methods of using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23590299A 1999-01-22 1999-01-22
US09/235,902 1999-01-22

Publications (2)

Publication Number Publication Date
WO2000042973A2 WO2000042973A2 (en) 2000-07-27
WO2000042973A3 true WO2000042973A3 (en) 2000-09-28

Family

ID=22887331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001602 Ceased WO2000042973A2 (en) 1999-01-22 2000-01-21 Homing pro-apoptotic conjugates and methods of using same

Country Status (5)

Country Link
EP (1) EP1150701A4 (en)
JP (1) JP4531267B2 (en)
AU (1) AU770381B2 (en)
CA (1) CA2359633A1 (en)
WO (1) WO2000042973A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520808A (en) * 2000-01-21 2003-07-08 ザ バーナム インスティチュート Chimeric prostate homing peptide with pro-apoptotic activity
JP2003522183A (en) * 2000-02-02 2003-07-22 トランジェーヌ、ソシエテ、アノニム Targeting peptide
CA2421872A1 (en) 2000-09-11 2002-03-14 Institut Pasteur Mechanism of mitochondrial membrane permeabilization by hiv-1 vpr, mimetics of vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of vpr with ant
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7192921B2 (en) 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
ATE419861T1 (en) * 2001-11-08 2009-01-15 Burnham Inst HOMING PEPTIDES FOR LYMPH VESSEL TUMOR AND THEIR USE
EP1346729A1 (en) * 2002-03-19 2003-09-24 Cardiovascular Research Institute Maastricht Targeting of myocardial angiogenesis through CD13/APN
WO2004007557A2 (en) * 2002-07-12 2004-01-22 Novo Nordisk A/S Tf antagonist
CA2519826A1 (en) 2003-03-24 2004-10-07 Nippon Medical School Foundation Cell death-inducing fusion gene specifically acting on cancer and product thereof
GB0312309D0 (en) * 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
US7598341B2 (en) 2003-10-31 2009-10-06 Burnham Institue For Medical Research Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
CA2594927A1 (en) * 2004-03-31 2005-10-13 Buck Institute Hunter-killer peptides and methods of use
CN102558334B (en) * 2004-09-07 2016-08-03 伯纳姆研究院 Selectivity anchors to the peptide in heart vasculature and related conjugates and method
AU2006320327A1 (en) * 2005-12-01 2007-06-07 Duke University Compounds and methods for inhibiting apoptosis
FI121959B (en) * 2008-05-09 2011-06-30 Pirjo Laakkonen Peptide seeking for brain tumors
EP2414389A1 (en) * 2009-04-01 2012-02-08 Schmidt-Wolf, Ingo Tumor targeting peptides, therapeutic and diagnostic compositions comprising the peptides
JP2013525285A (en) * 2010-04-08 2013-06-20 サンフォード−バーナム メディカル リサーチ インスティテュート Methods and compositions for enhancing delivery of compounds
WO2016172515A1 (en) 2015-04-23 2016-10-27 Sanford Burnham Prebys Medical Discovery Institute Targeted delivery system and methods of use therefor
KR101741594B1 (en) * 2015-06-30 2017-05-30 경북대학교 산학협력단 Pharmaceutical composition comprising fusion peptide targeting cancer cells and tumor associated macrophages for treating cancer and inhibiting metastasis
WO2017124147A1 (en) * 2016-01-19 2017-07-27 The University Of Western Australia Novel biomolecule conjugates and uses therefor
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11021529B2 (en) 2017-03-03 2021-06-01 Massachusetts Institute Of Technology Antimicrobial constructs and uses thereof
CN108314741B (en) * 2018-03-22 2021-08-03 中国人民解放军第四军医大学 A kind of tumor blood vessel targeting anticancer peptide NKL-DOTA and preparation method thereof
EP4139327A4 (en) * 2020-04-22 2024-10-02 Oncovolution, LLC PEPTIDE-PLATINUM COMPLEXES AND METHODS OF USE THEREOF
CN112830975B (en) * 2021-02-02 2023-03-10 西南交通大学 Pro-apoptotic bicyclic polypeptide with stable α-helical conformation, preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773292A (en) * 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US5789542A (en) * 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
US5928641A (en) * 1996-05-31 1999-07-27 Health Research Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010795A2 (en) * 1996-09-10 1998-03-19 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
ATE407943T1 (en) * 1998-03-13 2008-09-15 Burnham Inst TARGETING CONNECTIONS FOR VARIOUS ORGANS AND TISSUES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789542A (en) * 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
US5773292A (en) * 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US5928641A (en) * 1996-05-31 1999-07-27 Health Research Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARAP ET. AL.: "Cancer Treatment by Target Drug Delivery to Tumor Vasculature in a Mouse Model", SCIENCE, vol. 279, 16 January 1998 (1998-01-16), pages 377 - 380, XP002929458 *
ELLERBY ET. AL.: "Anti.-cancer activity of targeted pro-apoptotic peptides", NATURE MEDICINE, vol. 5, no. 9, September 1999 (1999-09-01), pages 1032 - 1038, XP002929458 *
See also references of EP1150701A4 *

Also Published As

Publication number Publication date
JP4531267B2 (en) 2010-08-25
CA2359633A1 (en) 2000-07-27
WO2000042973A2 (en) 2000-07-27
EP1150701A2 (en) 2001-11-07
EP1150701A4 (en) 2003-03-26
JP2002535258A (en) 2002-10-22
AU770381B2 (en) 2004-02-19
AU3348600A (en) 2000-08-07

Similar Documents

Publication Publication Date Title
CA2204535A1 (en) Molecules that home to a selected organ or tissue in vivo and methods of identifying same
CA2063886A1 (en) Polyethylene protein conjugates
AU2054097A (en) Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
WO1997029779A3 (en) EGF-Genistein conjugates for the treatment of cancer
CA2265484A1 (en) Tumor homing molecules, conjugates derived therefrom, and methods of using same
CA2172513A1 (en) Aminocyclohexylesters and uses thereof
EP2112161A3 (en) Peptides that lower blood glucose levels
CA2310850A1 (en) A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia
NZ503007A (en) Conjugates that contain the homeodomain of antennapedia
NO963283D0 (en) Non-viral vector
CA2174325A1 (en) Non-antigenic branched polymer conjugates
ZA979961B (en) 5-HT1F agonists
JP2002535258A5 (en)
EP1690552A3 (en) Radiopharmaceutical kits stabilised by means of cyclodextrins
CA2703688A1 (en) Use of bile acid or bile salt fatty acid conjugates
CA2120153A1 (en) Recombinant immunotoxins
SG48889A1 (en) Bicycle-polyamacrocyclocarboxylic acid complexes conjugates preparation and use as contrast agents
CA2337667A1 (en) Dextran-leptin conjugates, pharmaceutical compositions and related methods
AU3258197A (en) Peptides
WO2001074395A3 (en) Amiodarone-containing parenteral solution
AU5696298A (en) Keratinocyte growth factors and uses thereof
AU6132499A (en) Novel mercaptans and disulfides
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
AU7030700A (en) Preparation of highly pure toxin fragments
AU2002360350A1 (en) Peptides that home to tumor lymphatic vasculature and methods of using same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2359633

Country of ref document: CA

Ref country code: CA

Ref document number: 2359633

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 594432

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 33486/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000911617

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000911617

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 33486/00

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 2000911617

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000911617

Country of ref document: EP